For the full year, the company billed 41,586 tissue-based units and 45,700 liquid-based units, representing growth of 31% and 28%, respectively. Cash balance at year-end was $46.8M.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.